Akebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 174.19% and 158.19%, respectively, for the quarter ended June 2022. Do…
Börse:
-100,00%
Echtzeit-Aktienkurs Akebia Therapeutics Inc.
Bid:
Ask:
Nachrichtenticker der Akebia Therapeutics Inc. Aktie
Akebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 174.19% and 158.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...
Den vollständigen Artikel können Sie lesen unter: http://www.zacks.com/stock/news/1964409/akebia-therapeutics-akba-surpasses-q2-earnings-and-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-1964409.
Den vollständigen Artikel können Sie lesen unter: http://www.zacks.com/stock/news/1964409/akebia-therapeutics-akba-surpasses-q2-earnings-and-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-1964409.